# Steinar Engelsen

> Steinar Engelsen is a Series B investor at Teknoinvest backing Medical and Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Teknoinvest](https://shizune.co/investors/profile/teknoinvest)
- Total investments: 1
- Last investment: May 2004
- Lead investor: 100%
- Last updated: Aug 2026

Steinar Engelsen is a Series B investor at Teknoinvest focused on Medical and Health Care. Dr. Engelsen has been a member of Capnia's Board since 2003.Since November 1996, Dr. Engelsen has been a partner of Teknoinvest AS, a venture capital firm based in Norway. From 1989 until October 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and affiliatedcompanies. He was responsible for therapeutic research and development, most recently serving as Senior Vice President, Research and Development of Nycomed Pharma AS from January 1994 until October 1996. He is currently on the Board of Directors of Insmed, Inc (NASDAQ:INSM). In addition, from January to November 2000. Dr. Engelsen was acting Chief Executive Officer of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Engelsen also served as Chairman of the Board of Directors of Centaur.Dr. Engelsen received his MSc in Nuclear Chemistry.His MD from the University of Oslo.He is a Certified European Financial Analyst.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Oil and Gas | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CAPNIA | CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines andrelated symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition. | $12M | Series B | May 03, 2004 |  |

1 of 1 investments shown.

## Co-investors
- [Asset Management Ventures (AMV)](https://shizune.co/investors/profile/asset-management-ventures) — VC Fund, 1 deal together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 1 deal together

## About Teknoinvest

VC Fund · Oslo, Norway

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

2 contacts available at Teknoinvest.

| Name | Title | Profile |
| --- | --- | --- |
| Steinar Engelsen | Partner Oslo | https://shizune.co/investors/profile/steinar-engelsen |
| Rune Dybesland | Chief Financial Officer | https://shizune.co/investors/profile/rune-dybesland |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Steinar Engelsen invest in?

Steinar Engelsen invests primarily in Medical, Health Care and Oil and Gas startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Steinar Engelsen last invest?

The most recent investment recorded for Steinar Engelsen closed in May 2004. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co